SCHEMBL23779727

SCHEMBL23779727

c1cnc2c(c1)SNC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31243438 0.80
SCHEMBL31712937 0.80
SCHEMBL31712905 0.77
SCHEMBL20268047 0.73 HTR2A (0.31)
SCHEMBL20268057 0.73 HTR2A (0.31)
SCHEMBL20270019 0.70 DRD2 (0.33)
SCHEMBL20269076 0.70 DRD2 (0.33)
SCHEMBL20269635 0.70 DRD2 (0.33)
SCHEMBL31712913 0.69
SCHEMBL31332390 0.69 RYR2 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119072471-A Pyrazole substituted cyclopentyl ester derivative and application thereof 正大天晴药业集团股份有限公司 2024-12-03 CN claimed
CN-119072471-A Pyrazole substituted cyclopentyl ester derivative and application thereof 正大天晴药业集团股份有限公司 2024-12-03 CN disclosed
CN-117355532-A Tri-fused ring USP1 inhibitors and uses thereof 山东轩竹医药科技有限公司 2024-01-05 CN disclosed
CN-117337290-A Tri-ring ubiquitin-specific protease 1 inhibitors and uses thereof 山东轩竹医药科技有限公司 2024-01-02 CN disclosed
CN-117088874-A Diacylglycerol kinase inhibitors and uses thereof 轩竹生物科技股份有限公司 2023-11-21 CN disclosed
CN-116969943-A Tri-cyclic diacylglycerol kinase inhibitors and uses thereof 轩竹生物科技股份有限公司 2023-10-31 CN disclosed
CN-116731022-A Tri-ring ubiquitin-specific protease 1 inhibitors and uses thereof 轩竹生物科技股份有限公司 2023-09-12 CN disclosed
CN-116332944-A Tri-ring ubiquitin-specific protease 1 inhibitors and uses thereof 轩竹生物科技股份有限公司 2023-06-27 CN disclosed
EP-3873893-A1 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS Merck Sharp & Dohme Corp. (US) 2021-09-08 EP disclosed